Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice

Dose reduction of biologics for psoriasis could contribute to lower drug exposure. This study evaluated a one-step, tightly controlled, biologic dose reduction strategy in a prospective daily practice cohort. In patients with psoriasis with low disease activity using adalimumab, etanercept or usteki...

Descripción completa

Detalles Bibliográficos
Autores principales: ATALAY, Selma, VAN DER SCHOOT, Lara S., VANDERMAESEN, Laura, VAN VUGT, Lieke J., EILANDER, Mascha, VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367038/
https://www.ncbi.nlm.nih.gov/pubmed/33903920
http://dx.doi.org/10.2340/00015555-3815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367038/
https://www.ncbi.nlm.nih.gov/pubmed/33903920
http://dx.doi.org/10.2340/00015555-3815

Ejemplares similares